{
    "eid": "2-s2.0-85132820752",
    "title": "On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study",
    "cover-date": "2022-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Dermatology",
            "@code": "2708",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "biologics",
        "brodalumab",
        "interleukin-17 inhibitors",
        "ixekizumab",
        "Psoriasis",
        "secukinumab"
    ],
    "authors": [
        "Pim Sermsaksasithorn",
        "Chanidapa Wongtada",
        "Varin Chaaim",
        "Yuda Chongpison",
        "Pravit Asawanonda"
    ],
    "citedby-count": 0,
    "ref-count": 74,
    "ref-list": [
        "IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities",
        "The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis",
        "Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab",
        "The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment",
        "Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study",
        "Short-Term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network Meta-Analysis of randomized controlled trials",
        "A systematic review and Meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis",
        "Brodalumab: a new way to inhibit IL-17 in psoriasis",
        "Secukinumab: the anti-IL-17A biologic for the treatment of psoriasis",
        "Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis",
        "Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study",
        "Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study",
        "Brodalumab: the first anti-IL-17 receptor agent for psoriasis",
        "IL-17-targeting biologics aim to become standard of care in psoriasis",
        "A review of brodalumab, an IL-17 receptor antagonist, for moderate-to-Severe plaque psoriasis",
        "Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts",
        "Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition",
        "Long-Term Benefit-Risk profiles of treatments for moderate-to-Severe plaque psoriasis: a network Meta-Analysis",
        "Treatment patterns and pharmacoutilization in patients affected by psoriasis: an observational study in an Italian Real-World setting",
        "Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)",
        "Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study",
        "Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis",
        "Dose tapering of biologics in patients with psoriasis: a scoping review",
        "Intermittent use of biologic agents for the treatment of psoriasis in adults",
        "Intermittent etanercept therapy in pediatric patients with psoriasis",
        "Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study",
        "Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study",
        "Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study",
        "Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network Meta-Analysis",
        "Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis of PASI response",
        "Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis",
        "Rapid response of biologic treatments of moderate-to-Severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network Meta-analyses",
        "Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis",
        "Systemic pharmacological treatments for chronic plaque psoriasis: a network Meta-analysis",
        "A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study",
        "Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice",
        "A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial",
        "Early response is associated with stable Long-Term response in psoriasis patients receiving ixekizumab or ustekinumab",
        "Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain",
        "Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study",
        "Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials",
        "Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population",
        "Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study",
        "Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study",
        "Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry",
        "Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial",
        "Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis",
        "Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis",
        "Secukinumab without the initial loading dose in the treatment of plaque-type psoriasis\u2013a simplified dosing regimen at the expense of efficacy?",
        "Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka university psoriasis registry",
        "Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis",
        "Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab",
        "Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study",
        "Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies",
        "No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis",
        "Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice",
        "Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker\u2013a retrospective multicenter study",
        "Brodalumab to the rescue: efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics",
        "Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)",
        "Secukinumab in plaque psoriasis\u2013results of two phase 3 trials",
        "Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: real-world evidence in Japan",
        "Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients",
        "Real-world evidence of secukinumab in psoriasis treatment\u2013a meta-analysis of 43 studies",
        "Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study",
        "Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: an analysis of 75 patients in Taiwan",
        "Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events",
        "Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study",
        "A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis",
        "Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper",
        "Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis",
        "Biological therapy in patients with psoriasis: What we know about the effects on renal function",
        "Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks",
        "Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study",
        "Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): data from a multicenter Real-Life study in a cohort of Italian psoriatic patients that avoided secukinumab switching"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60002620",
        "affilname": "Faculty of Medicine, Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
        "affiliation-country": "Thailand"
    },
    "funding": []
}